The Biden administration’s final regulation affecting the Medicare Advantage industry would come with a much lighter touch ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A daily polypill was estimated to be cost-effective for primary CVD prevention among U.S. adults living in historically ...

The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...